Iron Infusions for Cancer Patients with Iron Deficiency Anemia

Assessment and Diagnosis

The European Society for Medical Oncology recommends assessing iron parameters using thresholds of serum ferritin <100 ng/mL for absolute iron deficiency and transferrin saturation (TSAT) <20% with serum ferritin >100 ng/mL for functional iron deficiency in cancer patients 1, 2
The American Society of Clinical Oncology defines anemia threshold as hemoglobin ≤11 g/dL or a decrease of ≥2 g/dL from baseline ≥12 g/dL in cancer patients 2

The European Society for Medical Oncology recommends administering IV iron monotherapy without erythropoiesis-stimulating agents (ESAs) for patients on chemotherapy with absolute iron deficiency 2
The American Society of Hematology recommends administering IV iron at a dose of 1000 mg, either as a single dose or in divided doses, for patients on chemotherapy with functional iron deficiency 2
The National Comprehensive Cancer Network recommends against administering IV iron on the same day as anthracyclines due to theoretical risk of potentiating cardiotoxicity 3

The American Society of Clinical Oncology recommends observing patients for at least 30 minutes following each IV iron administration for hypersensitivity reactions 4
The European Society for Medical Oncology recommends avoiding high-molecular weight iron dextran due to increased risk of anaphylactic reactions 3

The European Society for Medical Oncology reports that IV iron in cancer patients corrects iron deficiency anemia, reduces red blood cell transfusion requirements, and increases response rates to ESAs when used in combination 5

The European Society for Medical Oncology states that no clinical trials investigating IV iron with or without ESAs have shown induction or increased tumor progression 4

The European Society for Medical Oncology recommends administering IV iron at a dose of 1000 mg for breast cancer patients on tamoxifen with iron deficiency anemia, provided they are receiving chemotherapy, if they have absolute iron deficiency or functional iron deficiency 6
IV iron is strongly preferred over oral iron, as controlled trials demonstrate that oral iron provides no benefit compared to no iron at all, while IV iron substantially improves hematological response rates 7, 8

The American Society of Clinical Oncology recommends avoiding concurrent administration of IV iron with cardiotoxic chemotherapy, and instead administering it either before or after chemotherapy administration, or at the end of a treatment cycle—never on the same day 7, 9, 10
Patients should be observed for at least 30 minutes following each IV iron administration for hypersensitivity reactions, with trained staff and resuscitation facilities immediately available 7, 9, 10

Multiple controlled trials have shown no evidence of harm, with no induction or increased tumor progression in cancer patients receiving IV iron 7, 8, 9, 10, 11
When combined with ESAs, IV iron significantly improves response rates compared to ESA monotherapy 7, 8

The European Society for Medical Oncology (ESMO) guidelines define absolute iron deficiency as ferritin <100 ng/mL with TSAT <20%, and functional iron deficiency as ferritin 100-800 ng/mL with TSAT <20% 12, 13, 14
The American College of Physicians and other guideline societies recommend avoiding high-molecular weight iron dextran due to higher anaphylaxis risk, and instead using low-molecular weight iron dextran, ferric carboxymaltose, ferric derisomaltose, or iron sucrose 14
For functional iron deficiency, IV iron can be given alone or combined with erythropoiesis-stimulating agents (ESAs), though evidence for monotherapy in functional deficiency remains limited 12, 14

The National Comprehensive Cancer Network (NCCN) guidelines state that IV iron should never be administered during active infection, and should be avoided during neutropenia due to increased infection risk 12, 14
IV iron should be administered either before chemotherapy, after chemotherapy, or at the end of a treatment cycle, and never concurrently with cardiotoxic agents 12
Patients should be observed for at least 30 minutes following each IV iron infusion for hypersensitivity reactions, and trained staff and resuscitation facilities should be immediately available 12

IV iron significantly improves hematological response rates (93% vs 70% with ESA alone), reduces red blood cell transfusion requirements, and improves quality of life in some studies 12, 14
Multiple controlled trials show no evidence of tumor progression with IV iron, and no increased risk of infection or cardiovascular morbidity when given appropriately 12